On Friday, Establishment Labs Hldgs got a positive adjustment to its Relative Strength (RS) Rating, from 72 to 82.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique rating identifies price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an 80 or higher RS Rating as they begin their biggest price moves.
While Establishment Labs Hldgs is not near a proper buy zone right now, see if it is able to form and break out from a proper chart pattern.
The company reported 0% earnings growth in the latest quarterly report, while sales growth came in at 11%.
Establishment Labs Hldgs earns the No. 51 rank among its peers in the Medical-Products industry group. Boston Scientific, Insulet and ResMed are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
